Gilead Sciences (GILD) Intangibles (2009 - 2026)
Gilead Sciences' (GILD) quarterly Intangibles came in at $16.4 billion in Q1 2026, down 15.36% YoY from $19.4 billion in Q1 2025, and down 3.51% on a QoQ basis from $17.0 billion in Q4 2025.
Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Intangibles data on file, last reported at $16.4 billion in Q1 2026.
- Quarterly Intangibles fell 15.36% year-over-year to $16.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.4 billion (down 15.36% YoY) and the FY2025 annual result came in at $17.0 billion, down 14.89% from the prior year.
- Intangibles eased to $16.4 billion in Q1 2026, from $17.0 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $30.3 billion in Q1 2022 to a low of $16.4 billion in Q1 2026.
- A 5-year average of $23.8 billion and a median of $23.4 billion in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles slipped 6.54% — and 2024, when it dropped 24.59%.
- Tracing GILD's Intangibles over 5 years: stood at $28.9 billion in 2022, then retreated by 8.44% to $26.5 billion in 2023, then dropped by 24.59% to $19.9 billion in 2024, then declined by 14.89% to $17.0 billion in 2025, then declined by 3.51% to $16.4 billion in 2026.
- The last three Intangibles figures came in at $16.4 billion (Q1 2026), $17.0 billion (Q4 2025), and $18.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.03 Bn |
| Mar 31, 2026 | 16.38 Bn |
| Dec 31, 2025 | 16.98 Bn |
| Sep 30, 2025 | 17.97 Bn |
| Jun 30, 2025 | 18.57 Bn |
| Mar 31, 2025 | 19.36 Bn |
| Dec 31, 2024 | 19.95 Bn |
| Sep 30, 2024 | 20.55 Bn |
| Jun 30, 2024 | 22.83 Bn |
| Mar 31, 2024 | 23.43 Bn |
| Dec 31, 2023 | 26.45 Bn |
| Sep 30, 2023 | 27.15 Bn |
| Jun 30, 2023 | 27.75 Bn |
| Mar 31, 2023 | 28.35 Bn |
| Dec 31, 2022 | 28.89 Bn |
| Sep 30, 2022 | 29.44 Bn |
| Jun 30, 2022 | 29.89 Bn |
| Mar 31, 2022 | 30.33 Bn |
| Dec 31, 2021 | 33.46 Bn |
| Sep 30, 2021 | 33.90 Bn |